News

This contract, the first from a major US pharmaceutical company for MultiCell, allows Bristol-Myers Squibb to grow and use MultiCell’s immortalized Fa2N-4 hepatocytes for internal testing purposes. MultiCell’s

CytRx has assembled a team of renowned neurologists throughout the US to conduct the planned phase II clinical trial. The company announced in May that arimoclomol was granted

The initial phase I/II, open-label, dose-escalation trial of GRN163L will be conducted in patients with advanced chronic lymphocytic leukemia (CLL). The study is designed to demonstrate the safety

Cellzome is currently developing a series of small-molecule gamma secretase modulators (GSMs) for the treatment of Alzheimer’s disease. These compounds are directed towards preventing the formation of toxic

Alvesco (ciclesonide) is an inhaled corticosteroid with novel release and distribution properties. Inhaled corticosteroids, considered to be the foundation of asthma treatment, work by reducing inflammation – the

The collective data from phase II studies, presented at the centenary meeting of the American Thoracic Society (ATS), show indacaterol (QAB149) provides bronchodilation for up to 24 hours,

IBM’s Healthcare and Life Sciences unit said it has developed a framework, called Proof of Concept (PoC), that demonstrates how the Food and Drug Administration’s (FDA) Science of

The obesity study examined the association between body mass index and prostate cancer in 787 men undergoing biopsy due to an elevated tumor marker in the blood or

The five-year Alzheimer’s Disease Research Center grant, which will support more than 30 University of California, Irvine (UCI) faculty investigators, renews an expiring $6 million grant from the